The results from the current study extend these findings by suggesting that genetically-influenced lower TG via APOA5 have similar beneficial effects on CAD risk and the lipoprotein profile as genetically-influenced lower TG via LPL. Collectively, genetically-influenced lower TG through APOA5 and genetically-influenced lower TG through LPL were associated with an additively improved lipoprotein profile and CAD risk. This evidence concerns the gene APOA5 and coronary artery disorder.